Brain activity in an end-stage ALS patient suggests the presence of an unresponsive wakefulness syndrome.

Amyotroph Lateral Scler Frontotemporal DegenerJun 17, 2026 (epub)
Case ReportNeurology

Sandra Frycz, Wiktor Więcławski, Marcin Skotniczny et al.

✦ AI-curated · Sources linked

Case in brief

A 42-year-old woman with bulbar-onset, end-stage ALS and no means of communication underwent EEG and audiological assessment for covert consciousness. EEG showed prominent prefrontal 1–3 Hz activity, poorly differentiated power spectra, and no event-related potentials or 40 Hz auditory steady-state responses. Otoacoustic emissions were absent, and auditory brainstem responses indicated severe to profound hearing loss. The findings provided no electrophysiological evidence of covert consciousness and showed a profile resembling unresponsive wakefulness syndrome.

What made this case unusual

The electrophysiological profile in end-stage ALS resembled unresponsive wakefulness syndrome rather than supporting the assumption of preserved cortical function in complete locked-in syndrome; severe to profound hearing loss was also identified.

Diagnostic / clinical pearl

In end-stage ALS without communication, absent auditory EEG responses should be interpreted alongside assessment of auditory pathway integrity; this patient had severe to profound hearing loss as well as evidence of severe cortical dysfunction.

Why it matters

The case supports considering impaired consciousness, rather than persistent complete locked-in syndrome alone, as a possible framework for understanding some patients after advanced ALS.

Source

Published in Amyotroph Lateral Scler Frontotemporal Degener. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Neurology

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.